You have been prescribed this medicine if you have any of the following:
Treatment and prevention of fungal diseases of scalp which are accompanied by flaking and itching, such as:
– seborrheic dermatitis;
– localized tinea versicolor of scalp.
Skin and subcutaneous tissue:
erythema, burning sensation of the skin, itching, acne, contact dermatitis, skin irritation, rash, pustular rash at the application site, urticaria, xerosis, skin flaking enchancement, sense of discomfort, hypersensitivity.
Appendages of skin:
folliculitis, hair restructuring, excessive hair dryness or oiliness, hair loss (baldness), change in hair color (generally in patients with chemically damaged or gray hair), nail discoloration. There are known cases of straightening of naturally curly hair.
Nervous system and sense organs:
eye irritation, eyelid edema, excessive tearing, taste perversion (dysgeusia), paresthesia, hypersensitivity.
hypersensitivity reactions, including anaphylactoid reactions.
If it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to. Otherwise take it as soon as you remember and then go back to taking it as you would normally.
When assigning Dermazole Plus to patients who were treated with locally applied glucocorticoids for a long time, the treatment should be continued and cancelled gradually during 2-3 weeks (to avoid withdrawal syndrome).
Taking into account absence of significant systemic absorption a drug interaction with other drugs is unlikely.
As the shampoo is for external use only, and ketoconazole is almost unabsorbed into systemic blood flow, the development of overdose symptoms is unlikely.
In case of accidental ingestion of shampoo only supportive and symptomatic measures are used. Do not induce vomiting and perform gastric lavage to prevent aspiration.
Tell your doctor immediately if you become pregnant while taking this medication.
For safety of any drug during pregnancy or breastfeeding – please consult your doctor.
Store at the temperature not more than 25 С in a place protected from sunlight.
Keep it out of reach of children.
Active substance: citicoline sodium;
1 tablet contains citicoline sodium which is equivalent to citicoline 500 mg;
Excipients: lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, silica colloidal anhydrous, magnesium stearate, Opadry 03F58750 white covering.
⇒ Acute phase of a stroke.
⇒ Treatment of complications and consequences of a stroke.
⇒ Craniocerebral injury and its consequences.
⇒ Cognitive, sensitive, motor and neurological disorders caused by cerebral pathology of degenerative or vascular origin.
Recommended dose is 500 tо 2000 mg per day (1 – 4 tablets).
Doses of the preparation and treatment course duration depend on severity of cerebral lesion; they are adjusted by a doctor.
Elderly patients do not need the dose adjustment.
Adverse reactions occur very rarely (< 1/10000), including single cases.
hallucinations, excitement, insomnia.
headache, dizziness, tremor.
arterial hypertension or hypotension.
nausea, vomiting, gastric pain, hypersalivation, insignificant change of hepatic function indexes, diarrhea.
Skin: redness, urticaria, exanthem.
increase of body temperature, fever sensation, trembling, edema.
Neurodar® enhances effects of L-dihydroxyphenylalanine and levodopa.
It should not be synchronously used with drugs, which contain meclofenoxate.
Alcohol should not be consumed while the preparation usage.
Pregnancy and lactation:
Preparation administration during pregnancy and lactation period is possible only in case when the expected benefit for a mother overweights a potential risk for a fetus or baby.
There is no sufficient data concerning citicoline administration to children, therefore Neurodar® should not be administered to this age group of patients.
Neurodar® preparation should be administered with caution to patients who suffer from trimethylaminuria, Parkinson's disease and patients with depression in anamnesis.
Intoxication appearance is unlikely due to low toxicity, even in cases when the therapeutic doses are accidentally exceeded. In case of accidental overdose a symptomatic therapy is carried out.
Ability to influence reaction velocity while driving or operating any other mechanisms.
In individual cases, some central nervous system adverse reactions may affect the ability to drive a motor transport or operate complicated mechanisms. Therefore, it is necessary to be caution while driving motor transport or operating other machines during the treatment.
⇒ Hypersensitivity to components of the preparation.
⇒Supertension of parasympathetic nervous system.
Neurodar® is a nootropic preparation. Citicoline as a predecessor of key ultrastructural component of cell membrane (mainly phospholipids) has a wide spectrum of action:
it promotes a restoration of damaged cell membranes, inhibits an action of phospholipase, preventing a formation of free radicals and prevents cell death by acting on mechanisms of apoptosis.
Neurodar® is a source of choline, it increases a synthesis of acetylcholine and stimulates biosynthesis of structural (foot) phospholipids in neuron membrane.
It improves the transmission of nerve impulses in cholinergic neurons; it has a positive effect on plasticity of neuronal membranes and receptor function. It improves cerebral blood flow, enhances cerebral metabolic processes and activates the structure of cerebral reticular formation.
In acute phase of a stroke it reduces the volume of damaged tissue and improves cholinergic transmission.
Neurodar® alleviates symptoms, which occur during hypoxia and cerebral ischemia, including memory impairment, emotional lability, lack of initiative, difficulty during daily activities and self-service.
In craniocerebral injury it reduces the duration of post-traumatic coma and the severity of neurological symptoms.
Neurodar® has anti-edema properties and reduces cerebral edema due to its stabilizing effect on neuronal membrane.
It accelerates the recovery and reduces the duration and intensity of post-traumatic syndrome.
Neurodar® is effective in the treatment of cognitive, sensory and motor neurological disorders of degenerative and vascular etiology.
Citicoline is well absorbed in oral, intramuscular and intravenous introduction. After the preparation introduction it is observed a significant increase of choline in plasma. The preparation is almost completely absorbed in oral administration. Studies have shown that the bioavailability in per oral and parenteral routes of introduction was similar.
The preparation is metabolized in intestine and liver with the formation of choline and cytidine. After citicoline introduction it is assimilated by cerebral tissues, while cholines act on phospholipids, cytidine – on cytidine nucleoids and nucleic acids. Citicoline quickly reaches cerebral tissues and actively integrates into cell membrane, cytoplasm and mitochondria, activating an activity of phospholipids.
Only a minor part of introduced dose is excreted with urine and feces (less than 3%). Approximately 12% of introduced dose are excreted via respiratory tract. The preparation excretion via urine and respiratory tract has two phases: first phase – rapid excretion (with urine – within the first 36 hours, via airways – within the first 15 hours), the second phase – slow excretion. Major part of the dose is included into the process of metabolism.
General physic-chemical properties: white, capsule shaped, plain, coated tablets.
Store in a dry, protected from light place at the temperature not more than 25° C.
Keep it out of reach of children.
10 tablets are in a blister, 1 blister is in a carton box.
3 or 10 blisters are in a carton box no.30 (10×3) or no.100 (10×10).
Conditions of supply: